Physician profile
Allison Bell
NPI 1770077695
$12,779.21
in general payments reported to CMS, 2019-2025
27 companies · $3,926 in 2025
The $3,926 reported for 2025 was more than what 91% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,503 · 2023: $1,951 · 2024: $3,400 · 2025: $3,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,391 · Travel and Lodging: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,390.91 |
| Travel and Lodging | $1,885.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $7,092.88 | 2022-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Pain Management |
| Nevro Corp. | $2,031.89 | 2022-2024 | Senza |
| Medtronic, INC. | $938.59 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Saluda Medical Americas, INC. | $728.84 | 2022-2025 | Evoke, Evoke Scs |
| Abbott Laboratories | $325.57 | 2022-2024 | Proclaim, Axium, Eterna |
| Spr Therapeutics, INC | $194.81 | 2022-2024 | Sprint Pns System |
| Globus Medical, INC. | $173.59 | 2025 | Senza |
| Abbvie INC. | $165.88 | 2023-2025 | Botox |
| Nalu Medical, INC. | $156.81 | 2023-2025 | Nalu Neurostimulation System |
| Mml US, INC. | $154.20 | 2025 | Reactiv8 |
| Stimwave Technologies Incorporated | $136.12 | 2022 | |
| Collegium Pharmaceutical, INC. | $131.59 | 2024-2025 | Belbuca, Xtampza |
| Stryker Corporation | $99.94 | 2022-2025 | Spinejack |
| Protega Pharmaceutials INC | $55.45 | 2025 | Roxybond |
| Bioventus LLC | $54.98 | 2024-2025 | Durolane, Xcell |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $53.61 | 2024-2025 | Prospera |
| Scilex Pharmaceuticals INC. | $50.90 | 2024-2025 | |
| Forte Bio-Pharma LLC | $47.62 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Tersera Therapeutics LLC | $47.55 | 2024 | Prialt |
| International Rehabilitative Sciences, INC | $23.01 | 2023 | Rs 4i Plus Sequential Stimulator |
| Tonix Medicines, INC. | $20.07 | 2025 | Tonmya |
| Vertex Pharmaceuticals Incorporated | $18.12 | 2024 | |
| Electronic Waveform Lab, INC. | $17.62 | 2025 | |
| Fidia Pharma USA INC. | $16.04 | 2025 | Triluron, Hymovis |
| Ibsa Pharma INC. | $15.74 | 2024 | Tirosint, Licart |
| Avanos Medical | $14.17 | 2025 | Trivisc Sodium Hyaluronate |
| Pfizer INC. | $13.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.